CPA
CGON icon

Capital Performance Advisors’s CG Oncology CGON Stock Holding History

Capital Performance Advisors’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1
Closed -$38 – 635
2024
Q3 		$38 Buy
+1
New +$35 ﹤0.01% 2817

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Performance Advisors's CGON Position: Q4 2024 in Review

Capital Performance Advisors sold out of CG Oncology (CGON) in Q4 2024, closing a stake of 1 share — an estimated $38 sold.

Capital Performance Advisors first reported a position in CGON in Q3 2024 and held it in 1 quarter. The position peaked at $38 in Q3 2024. 140 funds tracked by Wall St. Rank hold CGON as of Q4 2024.

  • Capital Performance Advisors reported no remaining CG Oncology position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 1 CG Oncology share in Q4 2024, an estimated $38.
  • Capital Performance Advisors first reported a position in CG Oncology in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's CG Oncology position peaked at $38 in Q3 2024.
  • 140 funds tracked by Wall St. Rank held CG Oncology as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.